The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0

(1) Background: Fingolimod (Gilenya(®)) was the first oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Since its approval, the treatment landscape has changed enormously. (2) Methods: Data of PANGAEA and PANGAEA 2.0, two German real-world studies, were descriptively an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Schulze-Topphoff, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233755/
https://www.ncbi.nlm.nih.gov/pubmed/34208513
http://dx.doi.org/10.3390/jpm11060561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233755/
https://www.ncbi.nlm.nih.gov/pubmed/34208513
http://dx.doi.org/10.3390/jpm11060561

Ejemplares similares